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Abstract
Multiple Sclerosis (MS) is a chronic demyelinating disease of the central nervous 
system (CNS) in which inflammation plays a key pathological role. Recent evidences 
showed that systemic inflammation induces increasing cell infiltration within meninges 
and perivascular spaces in the brain parenchyma, triggering resident microglial and 
astrocytic activation. The anti-inflammatory enzyme A20, also named TNF associ-
ated protein 3 (TNFAIP3), is considered a central gatekeeper in inflammation and 
peripheral immune system regulation through the inhibition of NF-kB. The TNFAIP3 
locus is genetically associated to MS and its transcripts is downregulated in blood 
cells in treatment-naïve MS patients. Recently, several evidences in mouse models 
have led to hypothesize a function of A20 also in the CNS. Thus, here we aimed 
to unveil a possible contribution of A20 to the CNS human MS pathology. By 
immunohistochemistry/immunofluorescence and biomolecular techniques on post-
mortem brain tissue blocks obtained from control cases (CC) and progressive MS 
cases, we demonstrated that A20 is present in CC brain tissues in both white matter 
(WM) regions, mainly in few parenchymal astrocytes, and in grey matter (GM) 
areas, in some neuronal populations. Conversely, in MS brain tissues, we observed 
increased expression of A20 by perivascular infiltrating macrophages, resident-activated 
astrocytes, and microglia in all the active and chronic active WM lesions. A20 was 
highly expressed also in the majority of active cortical lesions compared to the 
neighboring areas of normal-appearing grey matter (NAGM) and control GM, par-
ticularly by activated astrocytes. We demonstrated increased A20 expression in the 
active MS plaques, particularly in macrophages and resident astrocytes, suggesting 
a key role of this molecule in chronic inflammation.
INTRODUCTION
Multiple Sclerosis (MS) is one of the most common chronic-
inflammatory, immune-related disease of the central nervous 
system (CNS), characterized by demyelination, glia altera-
tions, and neuro-axonal damage (16, 33). In this complex 
disorder, there is an interplay between inflammatory and 
neurodegenerative processes, leading to intermittent neuro-
logical disturbance followed by progressive accumulation of 
sensory-motor dysfunctions and cognitive disability.
Focal inflammatory demyelinating lesions in the white 
matter (WM), typically called “plaques,” have been 
historically considered the neuropathological hallmark of 
MS (33, 34). In the last years, pathological and MRI stud-
ies have revealed that lesions are also located and widely 
extended in the grey matter (GM), especially in the cerebral 
cortex (9, 11, 17).
Although the etiology of MS remains poorly understood, 
its complex multifactorial nature involving genetic suscep-
tibility, epigenetic and environmental factors is widely known. 
Among the genomic regions associated to MS in genome-
wide association studies (GWAS) (3) there is the locus 
containing the TNF associated protein 3 (TNFAIP3) gene, 
which encodes for the ubiquitin-editing enzyme A20.
Brain Pathology 31 (2021) 283–296
© 2020 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology
284
A20 in the neuropathology of Multiple Sclerosis Perga et al
A20 is an inducible cytoplasmic protein, whose functions 
make it a central gatekeeper in inflammation and immunity 
(14). Above all, A20 is considered the most potent negative 
regulator of the pro-inflammatory transcription factor NF-kB. 
A20 has proved to be necessary for the homeostasis of 
immune cells such as B cells, T cells, dendritic cells, and 
macrophages (64). Recently, new functions emerged, includ-
ing the control of necroptosis and inflammasome activity 
in immune cells (15).
An A20 dysfunction has been involved in the pathogenesis 
of several autoimmune and inflammatory disorders, includ-
ing MS. An expanding list of common coding and noncoding 
single-nucleotide polymorphism (SNPs) variants in the 
TNFAIP3 locus has been associated with an increased sus-
ceptibility to inflammatory disorders such as systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA), psoriasis, 
type 1 diabetes, coeliac disease, Crohn’s disease, and systemic 
sclerosis, (6, 10, 32, 38, 48).
A decreased level of A20 transcript has been found in 
blood cells of patients with MS, RA, or SLE compared 
to healthy controls (19, 20, 35, 49, 52, 53), and recent 
evidences describe an altered A20 expression also in immune 
cells of patients with neurodegenerative disorders such as 
Parkinson’s disease (53). In mice, a specific A20 deletion 
in immune cells triggers inflammatory phenotypes mimicking 
those seen in the genetically associated human disorders 
(12, 24, 26, 31, 42, 60). Consistently, in humans the “Haplo-
insufficiency of A20” (HA20), a monogenic disease char-
acterized by rare familial A20 mutations and a reduced 
A20 protein expression, leads to generalized inflammation 
in patients (59).
Besides the role in immune cells, NF-kB pathway and 
its inhibitor A20 have a well-known role in non-hematogenous 
organ-resident cells, particularly in the CNS, in both physi-
ological and pathological conditions. Neurons exhibit a high 
constitutive activity of NF-kB, which is involved in learning 
and memory and in the regulation of neurogenesis, neuri-
togenesis, and synaptogenesis (43, 44, 50). In contrast, in 
astrocytes and in microglia the NF-kB activity is promptly 
induced by pro-inflammatory molecules, accompanied by the 
production of a specific pattern of cytokines and chemokines 
and reactive nitrogen and oxygen species (58). In fact, it 
appears that the detrimental action of NF-kB in CNS dis-
orders takes place mostly in glial cells and not in neurons 
(2, 27, 29, 37, 41, 57). A chronic activation of NF-kB 
pathway in infiltrating and resident glia CNS cells in or 
near active lesions has been described as an hallmark of 
the neurodegenerative process occurring in MS and others 
neurodegenerative disorders (5, 23). The regulatory mecha-
nisms of the NF-κB activity are not completely understood, 
but studies in murine models provide evidence that A20 is 
crucial for NF-κB pathway regulation also in the CNS. The 
partial or complete germinal deficiency of A20 in mice 
causes spontaneous neuroinflammation in puppies with 
remarkable reactive microgliosis and astrogliosis (22). The 
selective ablation of A20 in astrocytes, but not in neurons, 
aggravate the outcome of experimental autoimmune encepha-
lomyelitis (EAE) as a result of increased chemokines pro-
duction and pro-inflammatory T lymphocytes recruitment 
in the spinal cord, due to an increased function of NF-kB 
(62). A20 deficiency in microglia determines an increase of 
the microglial cell number and exacerbates the EAE course, 
due to the uncontrolled activation of Nlrp3 inflammasome 
and the subsequent increased IL-1b secretion and CNS 
inflammation (45, 61).
Pranski et colleague observed the expression of A20 tran-
scripts and proteins belonging to A20 ubiquitin-editing 
complex in several area and cell types of control cases 
post-mortem brain tissues, such as neurons in cerebral cortex 
and glia-like cells in white matter (55). Furthermore, a recent 
molecular and neuropathological study of cortical lesions 
in post-mortem MS brain tissues has suggested that the 
overexpression of the A20 gene, together with HSP70, is 
related to the upregulation of the TNF/TNFR1-stimulated 
necroptotic signaling in conditions of increased meningeal 
inflammation and severe and rapid disease progression (39), 
which could possibly suggests its role in the inhibition of 
survival/repair pathways. However, A20 protein expression 
has never been detected in brain tissues. On this basis, we 
aimed to perform a neuropathological characterization of 
A20 protein and gene expression in human healthy and 
pathological brain tissues, focusing on MS disease.
MATERIALS AND METHODS
Human post-mortem snap-frozen brain tissues
For this study, 38 brain tissue blocks obtained from five 
control cases (CC) with no neurological diseases and 11 
secondary progressive (SP) and six primary progressive (PP) 
MS cases were used. Demographic and clinical features are 
reported in Table 1. Post-mortem brains were cut into blocks 
(2x2x1cm) and unfixed blocks were immediately frozen by 
immersing in isopentane, pre-cooled on a bed of dry ice 
and stored at −75°C. Human post-mortem brain tissues were 
obtained from the United Kingdom (UK) MS Tissue Bank 
at Imperial College via a UK prospective donor scheme with 
full ethical approval (08/MRE09/31). Neuropathological con-
firmation of the diagnosis of MS was carried out according 
to the International Classification of Diseases of the Nervous 
System criteria (www.ICDNS.org), and confounding patholo-
gies were excluded, including Alzheimer-like changes (56).
The project has been approved by the University Bioethics 
Committee of the University of Turin on 28 February 2015.
Neuropathological characterization of human 
post-mortem snap-frozen brain tissue by 
immunohistochemistry
Air-dried 10-µm-thick cryosections cut from snap-frozen tis-
sue blocks were characterized by immunohistochemistry 
(IHC) with specific antibodies. The complete list of used 
antibody, the working dilution and the postfixation method 
are reported in Table  2. Immunostaining for myelin-oligo-
dendrocyte glycoprotein (MOG) was performed to discrimi-
nate presence of white matter (WM) and grey matter (GM) 
and for the occurrence and extension of demyelinated lesions 
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in WM (WML) and GM (GML). Immunostaining for major 
histocompatibility complex class II (MHC II) molecules was 
performed to assess the stage of lesion activity. The poly-
clonal anti-A20 antibody was used to detect A20.
Primary antibodies indicated in Table  2 were diluted in 
PBS containing 0.1% of Triton X-100 and 10% of normal 
serum and incubated overnight at 4°C. Next, sections were 
incubated with the appropriate biotinylated secondary anti-
bodies (Jackson ImmunoResearch Laboratories, West Grove, 
PA), followed by avidin-biotin peroxidase complex (ABC; 
Vector Laboratories Burlingame, CA). The immune reactions 
were visualized with 3′3-diaminobenzidine (DAB, Sigma, St. 
Louis, MO). Hematoxylin was used to counter-stain nuclei 
in the slices. All the sections were sealed with DPX (Sigma, 
St. Louis, MO).
Control blocks contained normal WM and GM areas, 
while MS blocks included normal-appearing WM (NAWM), 
normal-appearing GM (NAGM), and lesions. Pre-active 
(pre-AL), active (AL), and chronic active (CAL) WM lesions 
(WML) and active (aGML) or inactive (iGML) GM lesions 
(GML) were identified based on the anti-MHC II immu-
nostaining according to Reynolds and colleagues (56).
The quantification of the A20 immunoreactivity in the 
lesions and in the normal-appearing areas was performed 
Table 1. Demographic and clinical data of examined MS patients and CC, provided by the UK MS Tissue Bank. Abbreviations: F = female; 
M = male; CC = control case; MS = multiple sclerosis; SPMS = secondary progressive multiple sclerosis; PPMS = primary progressive multiple 
sclerosis.
Case Gender Diagnosis
Disease length 
(years) Age of death Cause of death
Post-mortem 
delay (hours)
C08 F CC - 93 Broncho-pneumonia, cerebrovascular accident 9
C14 M CC - 64 Cardiac failure 18
C15 M CC - 82 - 21
C22 F CC - 69 Lung cancer 33
C25 M CC - 35 Carcinoma of tongue 22
MS104 M SPMS 11 53 Advanced MS, urinary tract infection 12
MS122 M SPMS 16 44 Broncho-pneumonia 16
MS154 F SPMS 10 34 Pneumonia 12
MS163 F SPMS 6 45 Multi-organ failure septicemia due to urinary tract infection, MS 28
MS166 F SPMS 36 62 Broncho-pneumonia, MS 7
MS187 F SPMS 30 57 Left ventricular failure, myocardial infarct, ischemic heart 
disease, sepsis, ms
13
MS197 F SPMS 27 51 Broncho-pneumonia, MS 10
MS200 F SPMS 19 44 Urinary tract infection, sepsis, MS 20
MS207 F SPMS 25 46 Pneumonia, MS 10
MS230 F SPMS 20 42 MS 31
MS245 M SPMS 26 64 Broncho-pneumonia, MS 25
MS248 F PPMS 16 58 C.O.P.D., multiple sclerosis 17
MS273 M PPMS 31 61 Urinary tract infection, septicemia, MS 24
MS325 M PPMS 2 51 Broncho-pneumonia 13
MS383 M PPMS 8 42 Aspiration pneumonia 17
MS398 F PPMS 28 57 Broncho-pneumonia, MS 28
MS473 F PPMS 13 39 Broncho-pneumonia, MS 9
Table 2. List of antibodies used for neuropathological characterization of human post-mortem snap-frozen brain tissue by Immunohistochemistry 
(IHC) and immunofluorescence (IF). Abbreviations: MOG = myelin-oligodendrocyte glycoprotein; MHC II = major histocompatibility complex class II 
molecules, GFAP = glial fibrillary acidic protein; NEFH = neurofilament heavy chain; PFA = paraformaldehyde.
Antigen Host Clonality Clone Dilution for IHC/IF
Working post-fixation 
method Code Source Marker
MOG Rabbit Polyclonal - IHC 1:200 Cold Methanol 12690-1-AP Proteintech myelin
MHCII Mouse Monoclonal C3/43 IHC 1:200; IF 1:100 IHC Ethanol; IF 4% 
PFA
M0775 Dako antigen presenting 
cells
A20 Rabbit Polyclonal - IHC 1:100; IF 1:50 4% PFA ab74037 Abcam A20
CD4 Mouse Monoclonal MT310 IF 1:50 4% PFA sc-19641 Santa Cruz Biotech. T helper cells
CD8 Mouse Monoclonal UCH-T4 IF 1:50 4% PFA sc-1181 Santa Cruz Biotech. cytotoxic T cells
CD68 Mouse Monoclonal 514H12 IF 1:50 4% PFA MCA1851T AbD Serotec macrophages
CD20 Mouse Monoclonal - IF 1:50 4% PFA M0755 Dako B cells
GFAP Mouse Monoclonal 5C10 IF 1:100 4% PFA ab190288 Abcam astrocytes
NEFH Mouse Monoclonal N52.1.7 IF 1:100 4% PFA MAB9540 Abnova neurons
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on IHC images obtained by frozen brain sections deriving 
from 10 SPMS and 3 PPMS cases. A picture containing 
lesions and neighboring normal-appearing matter was 
obtained for each tissue block by combining several IHC 
images acquired at 4X magnification with Nikon Eclipse 
microscope. Total coverage area, number of sections, mean 
and standard deviation (SD) of the section area were the 
following: 2.6  ×  108  µm2 (8 sections, mean 3.7*107  µm2, 
SD 4.6  ×  107) for the AL; 1.2  ×  108  µm2 (12 sections, 
mean 1.1  ×  107  µm2, SD 9.6  ×  106) for the CAL; 
2.8  ×  108  µm2 (20 sections, mean 1.4  ×  107  µm2, SD 
1.6  ×  107) for the matched NAWM; 1.6  ×  107  µm2 (27 
sections, mean 5.8 × 105 µm2, SD 8.5 × 105) for the aGML; 
2.7 × 106 µm2 (9 sections, mean 3.0 × 105 µm2, SD 2.0 × 105) 
for the iGML; 1.3  ×  107  µm2 (36 sections, mean 
3.5  ×  105  µm2, SD 3.2  ×  105) for the NAGM.
Images were acquired and analyzed with Nikon Eclipse 
microscope. A20 densitometric analysis was manually per-
formed on IHC images using ImageJ. Signal intensity, cor-
responded to the mean pixel intensity of the area, ranged 
from 0 (=white or total absent) to 255 (=black or total 
present). The A20 optic density (OD) in lesions area was 
normalized for the background by subtracting the OD value 
of the normal-appearing neighboring area.
Immunofluorescence
For indirect double immunofluorescence (IF), air-dried 
10-µm-thick cryosections cut from snap-frozen tissue blocks 
were stained with the A20-specific polyclonal antibody and 
the following mouse monoclonal antibodies reported in Table 2: 
anti-CD4, anti-CD8, anti-CD68, anti-CD20, anti MHC II, 
anti-GFAP, and anti-NEFH. For antibodies directed against 
CNS markers (i.e., anti-MHC II, anti-GFAP, and anti-NEFH 
antibodies) a final incubation with 0.05% Sudan Black B 
(SBB) (Sigma Aldrich) for 5  minutes a room temperature 
(RT) was performed to efficiently reduce the auto-fluorescence 
signal of the snap-frozen brain tissues. Staining was visualized 
using secondary antibodies Alexa Fluor 488 conjugated donkey 
anti-mouse IgG and Alexa Fluor 555 conjugated donkey anti-
rabbit IgG (Invitrogen, Eugene, OR). Sections were sealed in 
ProLong Gold anti-fade reagent with 4′,6′-diamidino-2-phe-
nylindole (DAPI, Invitrogen, Carlsbad, CA). Images were 
acquired using Leica TCS SP5 confocal microscope.
Total RNA extraction, retrotranscription, and 
gene expression analysis from human brain 
tissues
For RNA extraction, 50-μm-thick cryosections were cut from 
selected snap-frozen tissue blocks from CC and MS cases. 
The area of interest (WM, GM, NAWM, NAGM, and 
relative lesions) were identified based on immunohistochem-
istry characterization with anti-MOG and anti-MHC II 
antibodies and manually dissected. The dissection was per-
formed by gently incising the frozen tissue blocks with a 
needle, before performing the cut of the tissue block. Two 
or three cryosections were obtained from each tissue block, 
depending of the size of the area of interest.
Total RNA was extracted from the cryosections using the 
RNeasy Lipid Tissue Mini Kit (#74804, Qiagen, Hilden, 
Germany), according to the manufacturer’s instruction. Total 
RNA was reverse-transcribed at final concentration of 20  ng/
μL using random hexamer primers (High-Capacity cDNA 
Reverse Transcription Kit, #4368814, Thermo Fisher Scientific). 
Gene expression analysis was performed by real-time PCR 
using Applied Biosystems’ TaqMan gene expression products 
(Thermo Fisher Scientific) for the following genes: A20, TNFR1, 
TNFR2; TNF, IL1B, CXCL10, TGFb, IL10, IL6, NF-kB, 
STAT3, TRAFF6, CASP3, CASP8, BCL2, and XIAP. 
Transcriptional expression was normalized using GA3PDH as 
a housekeeping gene. Expression levels of the analyzed genes 
were calculated by the normalized comparative cycle threshold 
(Ct) method (2−ΔΔCt), using the Universal Human Reference 
RNA (Stratagene, Santa Clara, California) for calibration.
Statistical analysis
Normality of  distributions was assessed by graphical inspec-
tion and by the Shapiro–Wilk test. A20 OD was compared 
between lesioned and neighboring normal-appearing areas 
of  MS cases by means of  the paired Mann–Whitney U 
test. Normalized OD signals of  AL and CAL and of 
iGML and aGML were compared by the Mann–Whitney 
U test. The association between A20 levels and clinical 
and demographical variables was evaluated by regression 
models. Kruskal–Wallis with Dunn post hoc test was 
applied to compare gene expression data between CC 
samples and normal-appearing or lesioned areas of  MS 
cases. Lesioned and neighboring normal-appearing areas 
of  MS cases were compared by the paired Mann–Whitney 
U test. p-values were adjusted for multiple comparisons 
using the false discovery rate (fdr) correction. Spearman 
correlation was evaluated between gene expression data. 
Statistical analyses were performed using R software 3.5.3 
version (www.r-proje ct.org).
RESULTS
Characterization of A20 protein expression in 
human post-mortem control brain tissues
To investigate the A20 protein expression in brain, we per-
formed IHC and double IF using A20-specific antibodies 
on brain slices from 5 CC. In both WM (Figure  1A-D) 
and GM (Figure  1E-J) of CC, the IHC revealed the A20 
expression in cells morphologically resembling astrocytes 
(Figure  1C-C′ and I-I′) and the double confocal IF con-
firmed that A20 is basally expressed by scattered GFAP-
positive (GFAP+) astrocytes (Figure  1D, J and Figure S1). 
In GM, the IHC also showed the A20 expression in the 
perinuclear area of cells morphologically resembling neurons 
(Figure  1G-G′), as confirmed by double confocal IF show-
ing a population of NEFH+ neuronal cells expressing A20 
(Figure  1H and Figure S1). We did not detect A20 in 
MHC II+ microglial cells in either WM or GM (data not 
shown).
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Characterization of A20 protein expression in 
NAWM and WML in human post-mortem MS 
brain tissues
We further evaluated A20 expression in human post-mortem 
brain tissues from progressive MS patients, both in normal-
appearing and demyelinated areas of WM and GM. In 
NAWM (Figure 2A-E′) of MS cases, we detected A20 expres-
sion on ramified cells resembling astrocytes (Figure  2C-C′). 
Double confocal microscopy analysis demonstrated that the 
A20+ cells were mostly GFAP+ astrocytes, although not all 
the astrocytes expressed A20 (Figure  2D-D′ and Figure S2). 
However, differently from the CC WM, we observed A20 
expressed also by few MHC II+ microglia cells (Figure  2E-
E′ and Figure S2). In the demyelinated area (Figure  2F-M′), 
including pre-AL, AL, and CAL, we detected A20 expressed 
by a huge number of highly ramified resident cells (Figure 2H-
H′ and L-L′). Particularly in CAL we observed a greater 
number of ramified cells expressing A20 in the active plaque 
rim compared to few A20+ cells in the lesion core (Figure 2L-
L′). Double confocal microscopy clarified that in WML A20 
is expressed by all the GFAP+ astrocytes (Figure  2I-I′ and 
Figure S2) and by numerous MHC II+ microglia cells 
(Figure  2M-M′ and Figure S2). In addition, we detected 
A20 in perivascular infiltrates in or near the active lesions 
(Figure  3C-C′). Double confocal microscopy showed 
that A20 was not expressed by lymphocyte populations 
including CD4+ T helper (Th), CD8+ cytotoxic T cells, and 
CD20+ B cells (Figure  3D-O′). However, it was expressed 
by almost all the CD68+-activated microglia/macrophages 
(Figure  3P-S′).
Characterization of A20 protein expression in 
NAGM and GML in human post-mortem MS 
brain tissues
In the NAGM (Figure  4A-H), the A20 expression was 
observed in the perinuclear area of  groups of  cells mor-
phologically resembling neurons (Figure  4C-C′) and in rare 
scattered ramified cells (Figure 4G-G′). Confocal IF analysis 
revealed that, similar to CC GM, in NAGM A20 is expressed 
in the soma of some NEFH+ neurons (Figure  4D and 
Figure S3) and in sporadic GFAP+ astrocytes (Figure  4H 
and Figure S3). On the contrary, in aGML (Figure  4I-L) 
A20 expression was detected in a network of ramified cells 
(Figure  4K-K′), demonstrated to be GFAP+ astrocytes by 
double confocal IF (Figure  4L and Figure S3). We did 
not observe a co-localization of A20 and MHC II+ 
staining (data not shown), but this could be due to the 
intense A20 signal of  the astrocytes network, thus, we could 
not exclude that A20 is also expressed by some microglia 
cells.
Quantification of A20 protein expression in 
human post-mortem MS brain tissues
To quantify the A20 protein expression in both WML and 
GML, we performed a densitometric analysis on IHC images 
Figure 1. Localization of A20 expression in human post-mortem CC 
brain tissues by IHC and IF. WM (A-D) and GM (E-J) were identified by 
anti-MOG immunostaining (A, E). The presence of microgliosis were 
identified by anti-MHC II immunostaining (B, F). In WM, A20 was 
expressed by cells with astrocyte morphology (C-C′) expressing GFAP 
astrocytic marker (D). In GM, A20 was expressed by cells with neuronal 
morphology with a perinuclear distribution (G-G′) expressing NEFH 
neuronal marker (H) and by rare cells with astrocytic morphology (I-I′) 
expressing GFAP astrocytic marker (J). The inserts in (C′, G′, and I′) 
show A20-positive cells in WM and GM at high magnification. In D, H, 
and J, the arrows indicate the colocalization of the A20 and the specific 
cell marker signals, while the arrowheads show the lacking of 
colocalization. Original confocal microscopy magnification: 40x. [Colour 
figure can be viewed at wiley onlin elibr ary.com]
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from 13 MS cases (10 SPMS and 3 PPMS). We excluded 
major differences in the A20 expression pattern between 
PPMS and SPMS by graphical inspection. When we exam-
ined all the MS cases together, for WML, we measured 
A20 optic density (OD) in 8 AL, 12 CAL, and 20 neigh-
boring NAWM areas, classified based on MOG and MHC 
II immunostaining. For AL, we considered the entire area 
of the lesion, while for CAL only the active rim. A20 OD 
was significantly higher in both AL and CAL compared 
to their neighboring NAWM (paired Mann–Whitney U test, 
P  =  0.0078 and P  =  0.0005, respectively) (Figure  5A,B). 
Furthermore, we compared normalized OD signals of AL 
and CAL, obtained by subtracting the OD value of the 
neighboring NAWM area to that of the lesion. As a result, 
we did not observe significant differences (Mann–Whitney 
U test, P  =  0.34) (Figure  5C).
For GML, we measured A20 OD in 27 aGML, 9 iGML, 
and 36 neighboring NAGM areas, classified through MOG 
and MHC II immunostaining. We found higher A20 immu-
noreactivity in the aGML as compared to the closest NAGM 
areas (paired Mann–Whitney U test, P < 0.0001) (Figure 5D). 
In contrast, we did not observed significant differences 
between A20 immunoreactivity in iGML and neighboring 
NAGM (paired Mann–Whitney U test, P = 0.10) (Figure 5E). 
As expected, A20 normalized expression was higher in the 
aGML compared to iGML (Mann–Whitney U test, 
P  <  0.0001) (Figure  5F).
Also, we did not highlight relevant correlations between 
A20 immunoreactivity in both WML and aGML and plaque 
dimension, demographical and clinical features of subjects, 
such as gender, MS type, disease length, age and cause of 
death, and post-mortem delay (data not shown).
Gene expression analysis of A20 and related 
molecules in human post-mortem CC and MS 
brain tissues
We further investigated the snap-frozen brain tissues of CC 
and MS cases by quantifying the gene expression level of 
A20 (Figure  6) and other 13 genes belonging to the A20 
pathways and involved in the regulation of inflammation 
and apoptosis (Figure  S4). In particular, we analyzed 4 
WM and 4 GM samples from 4 CC and 12 NAWM, 9 
WML, 12 NAGM, and 12 GML samples from 10 progres-
sive MS patients. Given the high variability between-subjects 
in the gene expression data, we first compared CC samples 
(WM and GM) with normal-appearing and lesioned areas 
of MS cases (Figure  6A,C), then, we restricted the 
Figure 2. Localization of A20 protein expression in WM of human post-
mortem MS brain tissues by IHC and IF. The presence of NAWM, pre-
active (pre-AL), active (AL), and chronic active (CAL) lesions was evaluated 
with MOG and MHC II immunostaining (A, B, F, G, J, K). In NAWM, A20 
was expressed by rare scattered ramified cells (C, C’) expressing GFAP 
astrocytic (D, D′) and MHC II microglial markers (E, E′). In the area of 
active demyelination, including AL and CAL (H, H′, L, L′), A20 was 
expressed by a huge number of highly ramified cells expressing GFAP 
astrocytic (I, I′) and MHC II microglia markers (M, M′). The inserts in (C′, 
D′, E′, H′, I′, L′, and M′) show A20-positive cells in NAWM and WML at 
high magnification. The arrows indicate the colocalization between A20 
and the cell-specific markers (MHC II or GFAP); the arrowheads indicate 
the lack of colocalization. Original confocal microscopy magnification: 
40x. [Colour figure can be viewed at wileyonlinelibrary.com]
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comparison of normal-appearing and lesioned areas of MS 
cases to matched samples from the same slice of brain 
tissue blocks (Figure  6B,D).
The A20 expression level was significantly higher in WML 
compared to both WM of CC and matched NAWM (WM 
vs. WML: Kruskal–Wallis with Dunn post hoc test, 
P  =  0.048; NAWM vs. WML: paired Mann–Whitney U 
test, P  =  0.008) (Figure  6A,B). A20 was more expressed 
also by GML compared to matched NAGM, although the 
difference was less pronounced than in the WM (paired 
Mann–Whitney U test, P  =  0.02) (Figure  6D). On the con-
trary, we did not observe significant differences between 
NAGM or aGML and GM of CC (Kruskal–Wallis test, 
P  =  0.27) (Figure  6C).
Figure 3. Characterization of A20 expression in perivascular infiltrates in 
human post-mortem MS brain tissue by IHC and IF. In the area of 
demyelination, A20 was found in perivascular infiltrates (C, C′), not expressing 
CD4 T helper (D-G′), CD8+ T cytotoxic (H-K′), or CD20 B lymphocytes 
markers (L-O′). Conversely, A20 was expressed by a high number of CD68+ 
macrophages infiltrating the active demyelinated lesions in WM (P-S′). The 
arrows indicate the colocalization between A20 and CD68 macrophage 
marker, while the arrowheads indicate the lack of A20 colocalization with 
cell-specific markers (CD4, CD8 or CD20). Original confocal microscopy 
magnification: 40x. [Colour figure can be viewed at wileyonlinelibrary.com]
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None of the genes belonging to the A20 pathways and 
involved in the regulation of inflammation and apoptosis 
showed significant differences among GM tissues (Figure S4). 
However, most of  them showed differences between WM 
tissues. TNF receptors 1 (TNFR1) and 2 (TNFR2), whose 
stimulation by TNFα induces an A20 upregulation, were 
higher expressed in the WML compared to the matched 
NAWM (paired Mann–Whitney U test, P  =  0.02 and 
P = 0.02, respectively) (Figure S4A-B). The pro-inflammatory 
cytokines TNFα and IL-1β, both able to upregulate A20 
expression through the binding to their receptors, showed 
higher levels in the WML compared to the neighboring 
matched NAWM (paired Mann–Whitney U test, P  =  0.02 
and P  =  0.02, respectively) (Figure  S4C-D). However, we 
did not observe any difference in the expression of the 
pro-inflammatory cytokine IL6 (Figure  S4E). The anti-
inflammatory/regulatory cytokines IL10 and TGFβ were 
highly expressed in the WML compared to the matched 
NAWM (paired Mann–Whitney U test, P  =  0.04 and 
P  =  0.008, respectively) and to WM of CC, although for 
TGFβ this difference was not significant after adjusting for 
multiple comparisons (Kruskal–Wallis with Dunn post hoc 
test, P  =  0.03 and P  =  0.11, respectively) (Figure  S4F-G). 
Regarding the apoptotic pathways, we observed higher 
expression levels of  the caspases CASP3 and CASP8 in 
the WML compared to the neighboring NAWM (paired 
Mann–Whitney U test, P  =  0.02 and P  =  0.008, respec-
tively) and, for CASP8 only, also compared to WM of 
CC (Kruskal–Wallis with Dunn post hoc test, P  =  0.04) 
(Figure  S4H-I). The anti-apoptotic molecule XIAP, but not 
BCL2, showed an increased expression in WML compared 
to matched NAWM (paired Mann–Whitney U test, P = 0.02) 
(Figure  S4J-K). Finally, the pro-inflammatory transcription 
factors NF-kB and STAT3 were highly expressed in WML 
compared to the matched NAWM (paired Mann–Whitney 
U test, P  =  0.02 and P  =  0.03, respectively) (Figure  S4L-
M). As shown in the correlation plots, A20 expression was 
significantly correlated with the expression level of  most 
of  the genes in its pathway, in both WML and GML 
(Spearman correlation coefficient, P  <  0.05) (Figure  S4N-
O). Notably, in WML the strongest correlation was observed 
between A20 and TNF-related molecules including TNF, 
TNFR1, and TNFR2, the caspases CASP3 and CASP8, 
the chemokines IL10 and TGFβ, the transcription factors 
STAT3 and NF-kB, which induce the expression of A20 
itself  (Spearman correlation coefficient  ≥  0.7, P  <  0.001). 
TNFR1, IL10, and CASP8 showed the higher correlation 
with A20 also in the GML (Spearman correlation coeffi-
cient  ≥  0.7, P  <  0.0001).
DISCUSSION
The key role of  A20 in immune system regulation and 
in restricting the inflammatory processes in periphery (38, 
40), as well as its involvement in inflammatory and auto-
immune diseases such as MS, is widely known (10, 14, 
Figure 4. Localization of A20 protein in GM of human post-mortem MS 
brain tissues by IHC and IF. The presence of active (aGML) and inactive 
(iGML) lesions in GM (GML) was evaluated with MOG and MHC II 
immunostaining (A B, E, F, I, J). In NAGM, A20 was expressed by some 
populations of cells with neuronal morphology, with somatic distribution 
(C, C′), expressing the NEFH marker (D). Furthermore, A20 was expressed 
by rare ramified cells resembling astrocytes (G, G′) expressing the GFAP 
astrocytic marker (H). Conversely, in the aGML A20 was expressed by a 
tick mantel of cells with astrocyte morphology (K, K′) expressing the GFAP 
astrocytic marker (L). The arrows indicate the colocalization between A20 
and the neuronal nuclei in the NAGM (D) and the colocalization of A20 with 
GFAP+ astrocytes in the NAGM (H, L); the arrowheads indicate neurons 
that do not express A20 (D). Original confocal microscopy magnification: 
40x. [Colour figure can be viewed at wileyonlinelibrary.com]
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19, 20, 52, 53, 63). However, recent data suggested an 
involvement of  A20 also in the pathophysiology of  CNS, 
especially in mouse model of  MS (1, 22, 36, 45, 51, 61, 
62). In humans, the distribution of  some components of 
the A20 ubiquitin-editing complex has been described in 
post-mortem brain tissues by Pranski and coauthors, but 
the study of  A20 has been limited by the difficulty to 
find an anti-A20 primary antibody working on this type 
of  tissues (55). Undoubtedly, close to the identification a 
suitable antibody working on snap-frozen human brain 
samples, the high quality of  the tissues obtained by the 
UK tissue bank, probably due to the standardized pro-
cedure of  preservation and freezing adopted, eased to 
detect the protein.
Here, we aimed to perform, for the first time to our 
knowledge, a neuropathological characterization of the A20 
expression in post-mortem brain tissues obtained from CC 
and MS patients, with both PP and SP form of the disease. 
We observed that A20 protein and transcript are expressed 
in brain tissues of healthy donors, both in the GM, by 
several neurons, and in the WM, by few parenchymal astro-
cytes. These data are in accordance with those of Pranski 
and colleagues (55), which described the presence of com-
ponents of the A20 ubiquitin-editing complex prevalently 
in neurons, in which NF-kB pathway is constitutively acti-
vated and involved in cell homeostasis and survival, and 
more rarely in glia cells. Unlike neurons, in glia cells as 
well as in the immune cells, A20 expression is minimal at 
the steady state. Conversely, A20 rapidly increases its expres-
sion upon NF-kB activation following stimulation with dif-
ferent factors including inflammatory cytokines and microbial 
derived products. In this way, A20 controls and restricts 
the NF-kB activity by a negative feedback loop mechanism 
(28).
In MS brain tissues, we observed a similar pattern of 
A20 expression in PP and SPMS, suggesting that they share, 
at least partially, some common inflammatory and/or regula-
tory mechanisms of responses to pathological conditions. 
Figure 5. Densitometric analysis of A20 immunoreactivity measured on 
IHC images of human post-mortem brain tissues of MS cases. The A20 
OD was compared between NAWM and AL (A) or CAL (B) and between 
NAGM and aGML (D) or iGML (E) (paired Mann–Whitney U-test, 
*P < 0.05, **P < 0.001, ***P < 0.0001). Normalized A20 OD signals, 
calculated by subtracting the OD value of the normal-appearing area to 
that of the matched lesion area, were compared between AL and CAL 
(C) and between aGML and iGML (F) (Mann–Whitney U test, *P < 0.05, 
**P  <  0.001, ***P  <  0.0001). [Colour figure can be viewed at 
wileyonlinelibrary.com]
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In addition, the distribution of the A20 protein in CNS 
resident cells of no-lesioned area was similar to that identi-
fied in the CC. Particularly, in the NAGM A20 was expressed 
by several neurons in the soma, while in the NAWM it 
was expressed by some highly ramified astrocytes and by 
few microglia cells.
On the contrary, A20 showed a very different pattern of 
expression in the demyelinated active lesions in both WM 
and GM. A20 protein was highly expressed in all the WML 
examined. In particular, in the CAL A20 was mostly expressed 
by a very dense network of reactive astrocytes in the active 
rim of the lesions, while in the AL it was mainly expressed 
by infiltrating macrophages along the whole area of injury, 
but not by B and T lymphocytes. In AL, as in the CAL, 
A20 was also expressed by astrocytes characterized by mas-
sive enlargement of the cell soma and reduced proves density, 
a hypertrophic morphology typical of astrogliosis reaction. 
We also observed A20 expression in some population of 
Figure 6. A20 gene expression analysis in human post-mortem brain 
tissues of MS and CC. The A20 expression was compared between WM 
of CC and NAWM and WML of MS cases (A), and between GM of CC 
and NAGM and aGML of MS cases (C) (Kruskal–Wallis with Dunn post 
hoc test, *P < 0.05, **P < 0.001, ***P < 0.0001). In addition, the A20 
expression was compared between matched samples of normal-
appearing and lesioned areas of MS cases (B, D) (paired Mann–Whitney 
U test, *P < 0.05, **P < 0.001, ***P < 0.0001). Relative gene expression 
was calculated by the normalized comparative cycle threshold (Ct) 
method 2−ΔΔC. [Colour figure can be viewed at wileyonlinelibrary.com]
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microglia, but the number of A20-positive microglia cells 
could be underestimated due to the massive presence of 
A20-positive reactive astrocytes in the same areas. 
Corroborating these data, Voet and colleagues described an 
overexpression of the A20 transcript in WML compared 
to NAWM control tissue of human post-mortem MS brain 
tissues (61).
Similarly to WML, in the majority of aGML a tick 
mantle of reactive astrocytes expressed A20 at high levels. 
We did not observed the A20 expression in other cell types, 
but, as for the WML, we cannot exclude it could have 
been hidden by the strong and compact A20 immunofluo-
rescence signal in astrocytes.
To this regard, neurons present in cortical lesions were 
previously demonstrated to overexpress A20 in combination 
with TNFR1. This profile of expression was associated to 
a gradient of neuronal loss from the CSF/pial surface toward 
the inner cortical layers (39).
In addition, we were not able to detect A20 in oligo-
dendrocytes, due to the lack of validated protocols for 
oligodendrocytes markers working after PFA fixation in 
frozen brain tissues (39).
Finally, we described the upregulation of  the gene expres-
sion of  several A20-related molecules in the WML com-
pared to NAWM, including upstream receptors inducing 
A20 expression such as TNFR1 and TNFR2, pro-inflam-
matory cytokines such as IL-1b and TNF-a, the transcrip-
tion factor NF-kB and STAT3, and the 
pro-apoptotic-molecules CASP3 and CASP8. We also 
observed the upregulation of  regulatory cytokines such 
us TGFβ and IL10 and anti-apoptotic enzymes such us 
XIAP, suggesting that negative feedback processes might 
possibly occur in some active lesioned areas. However, in 
the GML, we did not observe significant modulation of 
these molecules.
The high levels of A20 expression that we observed in 
the macrophages infiltrating the WML is line with the well-
known regulatory role of the enzyme in the immune system 
and in particular in the circulating myeloid cells, where it 
controls cell homeostasis and activation to prevent an abnor-
mal pro-inflammatory response (15, 40). Macrophages are 
the most predominant immune cell type in inflammatory 
demyelinating MS lesions. It is well established that foamy 
macrophages primarily promote MS disease progression by 
internalizing myelin debris, presenting brain-derived autoan-
tigens, and secreting pro-inflammatory mediators (13, 25). 
However, early studies show that they also promote axonal 
sprouting and remyelination (21, 30). This dual role can be 
explained by the fact that macrophages comprise several 
different phenotypical and functional subpopulations (46, 
47), thus, further experiments are needed to clarify the role 
of the enzyme in these cells.
Glia cells as well display different phenotypes and func-
tions. On the one hand, the microglia promotes neuroin-
flammatory and neurodegenerative events in MS by releasing 
inflammatory mediators. On the other hand, it supports the 
CNS repair through the production of neurotrophic factors 
and the clearance of myelin debris (4). Also astrocytes are 
early and active players in the lesion pathology (7, 54) and 
could exert both detrimental and beneficial effects (54). In 
active lesions, astrocytes assume a hypertrophic morphology 
and may sustain damage through the production of pro-
inflammatory cytokines and reactive oxygen species (7). In 
a later stage of lesion development, astrocytes may dampen 
inflammation through the secretion of BDNF and the expres-
sion of TLRs promoting neuroprotection and lesion repair 
(8, 18).
Contrary to the vast literature on A20 in blood peripheral 
cells, less is known on its role in glia cells. The completely 
germinal deficiency of A20 in mice causes spontaneous 
neuroinflammation in puppies, with remarkable reactive 
microgliosis and astrogliosis (22). Consistently, the selective 
ablation of A20 in astrocytes resulted in a more severe 
clinical course of the EAE, as a result of increased chemokines 
production and enhanced recruitment of pro-inflammatory 
T lymphocytes in the spinal cord (62). The specific A20 
deletion in microglia increases microglial cell number, affects 
microglial regulation of neuronal synaptic functions, and 
also exacerbates MS-like disease (45, 61).
According to the literature, here, we demonstrated the 
overexpression of A20 protein and transcript in glia cells, 
predominantly astrocytes, in both WML and GML of MS 
patients. In particular, we found reactive astrocytes express-
ing A20 in the active margin of demyelinating lesion extend-
ing into neighboring NAWM, suggesting possible contribution 
to lesion development. It would be of interest to investigate 
which type of astrocytes expresses the enzyme through double 
staining for A20 and astrocytic markers as well as in vitro 
or in vivo experiments on mouse models of 
demyelination.
CONCLUSION
Overall, our results support the hypothesis of  a specific 
role of  A20 in activated astrocytes and microglia, close 
to the well know role in the myeloid cells. However, they 
do not allow to determine whether it is beneficial or a 
detrimental, since glia cells display spatial- and temporal-
dependent identities in inflamed CNS. A20 could be involved 
in an attempt to regulate inflammation, or could actively 
induce demyelination and cell death sustaining the chronic-
inflammatory state, according to the inflammatory stimuli. 
Functional studies are necessary to shed light on this 
debate.
The knowledge of the role of the A20 pathway in these 
cells and in the ongoing inflammation during the progressive 
stage of MS could be crucial to design and address new 
therapeutic approaches.
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SUPPORTING INFORMATION
Additional supporting information may be found in the online 
version of this article at the publisher’s web site:
Figure S1. Identification of cell types expressing A20 in 
human post-mortem CC brain tissues by IHC and IF. A20 was 
expressed by rare astrocytes in WM and GM, as validated by 
double confocal immunofluorescence and confocal microscopy 
with GFAP astrocytic marker (A-D′ and I-L′). Additionally, in 
GM, A20 was also expressed by some population of NEFH+ 
neurons, with a perinuclear distribution, as shown by the 
colocalization of A20 with the DAPI nuclear staining (E-H′). 
The inserts in (D′, H′, and L′) show A20-positive cells in WM 
and GM at high magnification. Original magnification: 40X. 
The arrows indicate the colocalization between A20 and the 
cell-specific markers; the arrowheads indicate cells that do not 
express A20.
Figure S2. Identification of cell type expressing A20 in human 
post-mortem MS brain tissues by IHC and IF. In NAWM, A20 
was expressed by a subgroup of GFAP+ astrocyte (A-D′) and 
MHC II+ microglia cells (E-H′), while in the WML, A20 was 
expressed by all the GFAP+ astrocytes (I-L′) and by a higher 
number of MHC II+ cells (M-P′), as validated by double 
immunofluorescence and confocal microscopy. The inserts in 
(D′, H′, L′, and P′) show A20-positive cells in NAWM and 
WML at high magnification. Original magnification: 40X. 
The arrows indicate the colocalization between A20 and the 
cell-specific markers; the arrowheads indicate the lack of 
colocalization.
Figure S3. Identification of cell type expressing A20 in human 
post-mortem MS brain tissues by IHC and IF. In NAGM, A20 
was expressed in the perinuclear area of  some population 
of  neurons, identified with anti-NEFH neuronal marker 
(A-D′), and by some GFAP+ astrocytes (I-L′). In the area 
with aGML, A20 is expressed by neurons (E-H′) and by a fit 
network of  astrocytes, identified with GFAP-specific marker 
(M-P′) similarly to NAGM). The inserts in (D′, H′, L′, and 
P′) show A20-positive cells in NAGM and aGML at high 
magnification. Original magnification: 40X. The arrows 
indicate the colocalization between A20 and the cell-specific 
markers; the arrowheads indicate cells that do not express 
A20.
Figure S4. Gene expression analysis of molecules in the A20 
pathway: TNF receptors (A-B), pro- and anti-inflammatory 
cytokines (C-G), molecules involved in the apoptosis regulation 
(H-K) and pro-inflammatory transcription factors (L-M). The 
expression levels were compared between WM of  CC and 
NAWM and WML of  MS cases, and between GM of  CC 
and NAGM and aGML of  MS cases (Kruskal–Wallis with 
Dunn post hoc test, *P < 0.05, **P < 0.001, ***P < 0.0001). 
In addition, the A20 expression was compared between 
matched samples of  normal-appearing and lesioned areas 
of  MS cases (paired Mann–Whitney U test, *P  <  0.05, 
**P < 0.001, ***P < 0.0001). Relative gene expression was 
calculated by the normalized comparative cycle threshold 
(Ct) method 2−ΔΔC. Correlation plot of  genes in WM (N) 
and GM (O) (Spearman correlation coefficient, P < 0.05).
